These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26944771)

  • 1. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
    Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
    J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics, tolerability, and pharmacodynamics of metuzumab, a novel CD147 human-mouse chimeric and glycoengineered antibody.
    Zhang Z; Zhang Y; Sun Q; Feng F; Huhe M; Mi L; Chen Z
    Mol Cancer Ther; 2015 Jan; 14(1):162-73. PubMed ID: 25376611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples.
    Stubenrauch K; Wessels U; Essig U; Kowalewsky F; Vogel R; Heinrich J
    J Pharm Biomed Anal; 2013 Jan; 72():208-15. PubMed ID: 23017233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab.
    Li M; Li H; Gao K; Wang M; An W; Zhu Y; Ding L; Wang L; Gu J; Zuo C; Sun L
    J Immunol Methods; 2018 Jan; 452():6-11. PubMed ID: 29037956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.
    Wang M; Zhang S; Sun Q; Yang X; Wang Y; Shang R; Zhu Y; Yao H; Li Y
    Cancer Biol Ther; 2019; 20(12):1443-1452. PubMed ID: 31411555
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A generic anti-drug antibody assay for monoclonal antibody therapeutics with broad dynamic range eliminates the need for titer evaluation in preclinical studies.
    Li H; Foley AR; Shim J; Siradze K; Webb-Vargas Y; Sperinde G; Fischer SK
    J Pharm Biomed Anal; 2024 Oct; 249():116364. PubMed ID: 39047461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly frequent anti-idiotype antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting.
    Saito-Yabe M; Yoshigae Y; Takasaki W; Kurihara A; Ikeda T; Okazaki O
    Br J Pharmacol; 2009 Sep; 158(2):548-57. PubMed ID: 19645714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W; Jiang H; Titsch C; Haulenbeek JR; Pillutla RC; Aubry AF; DeSilva BS; Arnold ME; Zeng J; Dodge RW
    J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development, validation, and application of ELISA for detection of anti-HD105 antibodies in pre-clinical safety evaluation using monkeys.
    Choi WH; Jo HR; Jeon EJ; Youm SY; Jeon JS; Son YG; You WK; Koh WS; Lee SH; Kim SK
    J Pharm Biomed Anal; 2016 Nov; 131():309-315. PubMed ID: 27619177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.
    Rispens T; de Vrieze H; de Groot E; Wouters D; Stapel S; Wolbink GJ; Aarden LA
    J Immunol Methods; 2012 Jan; 375(1-2):93-9. PubMed ID: 21986105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies.
    Andersen DC; Koch C; Jensen CH; Skjødt K; Brandt J; Teisner B
    J Immunoassay Immunochem; 2004; 25(1):17-30. PubMed ID: 15038614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and specificity of monoclonal anti-idiotypic antibodies against human HIV-specific antibodies. I. Cross-reacting idiotopes are expressed in subpopulations of HIV-infected individuals.
    Müller S; Wang HT; Kaveri SV; Chattopadhyay S; Köhler H
    J Immunol; 1991 Aug; 147(3):933-41. PubMed ID: 1861082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a bridging ELISA for detection of antibodies against ZV0203 in cynomolgus monkey serum.
    Liu T; Tong Y; Gao J; Fang W; Wu J; Peng X; Fan X; Chen X; Sun J; Cao S; Li Z; Gong L; Qin Q; Ju D
    J Pharmacol Toxicol Methods; 2023; 119():107210. PubMed ID: 36028046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
    Liu Y; Reidler H; Pan J; Milunic D; Qin D; Chen D; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 64(3):238-45. PubMed ID: 21827863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.